These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 30588246)

  • 1. Potential Management of Circulating Tumor DNA as a Biomarker in Triple-Negative Breast Cancer.
    Shang M; Chang C; Pei Y; Guan Y; Chang J; Li H
    J Cancer; 2018; 9(24):4627-4634. PubMed ID: 30588246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Tumor DNA as a Novel Biomarker Optimizing Treatment for Triple Negative Breast Cancer.
    Sun Y; Zhu C; Xu F; Cui S; Guan X
    Clin Breast Cancer; 2023 Jun; 23(4):339-349. PubMed ID: 36966079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer.
    Cheng F; Su L; Qian C
    Oncotarget; 2016 Jul; 7(30):48832-48841. PubMed ID: 27223063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumour DNA (ctDNA) as a liquid biopsy for melanoma.
    Calapre L; Warburton L; Millward M; Ziman M; Gray ES
    Cancer Lett; 2017 Sep; 404():62-69. PubMed ID: 28687355
    [TBL] [Abstract][Full Text] [Related]  

  • 5.
    Arimura A; Sakai K; Kaneshiro K; Morisaki T; Hayashi S; Mizoguchi K; Yamada M; Kai M; Ono M; Nishio K; Nakamura M; Kubo M
    Cancers (Basel); 2024 Mar; 16(6):. PubMed ID: 38539518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating tumor DNA and circulating tumor cells in metastatic triple negative breast cancer patients.
    Madic J; Kiialainen A; Bidard FC; Birzele F; Ramey G; Leroy Q; Rio Frio T; Vaucher I; Raynal V; Bernard V; Lermine A; Clausen I; Giroud N; Schmucki R; Milder M; Horn C; Spleiss O; Lantz O; Stern MH; Pierga JY; Weisser M; Lebofsky R
    Int J Cancer; 2015 May; 136(9):2158-65. PubMed ID: 25307450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating tumor DNA for triple-negative breast cancer diagnosis and treatment decisions.
    Saliou A; Bidard FC; Lantz O; Stern MH; Vincent-Salomon A; Proudhon C; Pierga JY
    Expert Rev Mol Diagn; 2016; 16(1):39-50. PubMed ID: 26568208
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumour mutation detection in triple-negative breast cancer as an adjunct to tissue response assessment.
    Zaikova E; Cheng BYC; Cerda V; Kong E; Lai D; Lum A; Bates C; den Brok W; Kono T; Bourque S; Chan A; Feng X; Fenton D; Gurjal A; Levasseur N; Lohrisch C; Roberts S; Shenkier T; Simmons C; Taylor S; Villa D; Miller R; Aguirre-Hernandez R; Aparicio S; Gelmon K
    NPJ Breast Cancer; 2024 Jan; 10(1):3. PubMed ID: 38182588
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long non-coding RNAs: implications in targeted diagnoses, prognosis, and improved therapeutic strategies in human non- and triple-negative breast cancer.
    Rodríguez Bautista R; Ortega Gómez A; Hidalgo Miranda A; Zentella Dehesa A; Villarreal-Garza C; Ávila-Moreno F; Arrieta O
    Clin Epigenetics; 2018; 10():88. PubMed ID: 29983835
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parallel Analyses of Somatic Mutations in Plasma Circulating Tumor DNA (ctDNA) and Matched Tumor Tissues in Early-Stage Breast Cancer.
    Zhang X; Zhao W; Wei W; You Z; Ou X; Sun M; Yin Y; Tang X; Zhao Z; Hu C; Liu F; Deng J; Mao L; Zhou D; Ren Y; Li X; Zhang S; Liu C; Geng J; Yao G; Song B; Liu Y; Li D; Jiang Y; Chen Y; Zhao Y; Yu S; Pang D
    Clin Cancer Res; 2019 Nov; 25(21):6546-6553. PubMed ID: 31350313
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
    Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
    Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer.
    El Hejjioui B; Bouguenouch L; Melhouf MA; El Mouhi H; Bennis S
    Diagnostics (Basel); 2023 Jan; 13(3):. PubMed ID: 36766575
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
    Millis SZ; Gatalica Z; Winkler J; Vranic S; Kimbrough J; Reddy S; O'Shaughnessy JA
    Clin Breast Cancer; 2015 Dec; 15(6):473-481.e3. PubMed ID: 26051240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Response Monitoring Using a Tumor-Informed Circulating Tumor DNA Test in an Advanced Triple-Negative Breast Cancer Patient: A Case Report.
    Azzi G; Krinshpun S; Tin A; Maninder M; Malashevich AK; Malhotra M; Vega RR; Billings PR; Rodriguez A; Aleshin A
    Case Rep Oncol; 2022; 15(2):473-479. PubMed ID: 35702676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blood Circulating Non-Coding RNAs for the Clinical Management of Triple-Negative Breast Cancer.
    Powrózek T; Ochieng Otieno M
    Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Tumor DNA Abundance and Potential Utility in De Novo Metastatic Prostate Cancer.
    Vandekerkhove G; Struss WJ; Annala M; Kallio HML; Khalaf D; Warner EW; Herberts C; Ritch E; Beja K; Loktionova Y; Hurtado-Coll A; Fazli L; So A; Black PC; Nykter M; Tammela T; Chi KN; Gleave ME; Wyatt AW
    Eur Urol; 2019 Apr; 75(4):667-675. PubMed ID: 30638634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection of
    Rodriguez BJ; Córdoba GD; Aranda AG; Álvarez M; Vicioso L; Pérez CL; Hernando C; Bermejo B; Parreño AJ; Lluch A; Ryder MB; Jones FS; Fredebohm J; Holtrup F; Queipo-Ortuño MI; Alba E
    J Clin Med; 2019 Aug; 8(8):. PubMed ID: 31394872
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of basal-like breast cancer by circulating tumor DNA analysis.
    Wei W; Zhang X; Sun S; Xia B; Liang X; Cui Y; Gao S; Pang D
    Oncol Lett; 2018 May; 15(5):7389-7396. PubMed ID: 29725452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.
    Tzanikou E; Markou A; Politaki E; Koutsopoulos A; Psyrri A; Mavroudis D; Georgoulias V; Lianidou E
    Mol Oncol; 2019 Dec; 13(12):2515-2530. PubMed ID: 31254443
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Mastoraki S; Strati A; Tzanikou E; Chimonidou M; Politaki E; Voutsina A; Psyrri A; Georgoulias V; Lianidou E
    Clin Cancer Res; 2018 Mar; 24(6):1500-1510. PubMed ID: 29284708
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.